SLC5A5 and neoplasm: A series of preclinical studies have demonstrated the potential of CMV (cytomegalovirus) promoter driven MSC-mediated NIS gene delivery in xenograft tumor mouse models that have shown successful selective NIS expression in tumors and metastases plus a robust therapeutic response after [131I]NaI application [27–29].